New book by Larry Connors Click here Improve your trading - See how
* Neuralstem Inc. (AMEX: CUR | Quote | Chart | News | PowerRating) is on the cusp of filing and IND requesting clearance for human trials in the ALS indication, based on compelling data from research at the University of Michigan.
* Further, the Company recently triggered negotiations with a major equity investor for the sale of certain rights related to licensing for China licensing; we believe these rights could garner $5 million to $10 million (or more) based on recent transactions.
* The Company has sufficient cash on hand to complete the initial phase of human trials, which will likely involve 10-12 patients.
* We are maintaining our twelve-to-eighteen month price objective of $6.70 (+372%).
Neuralstem Inc engages in the research and development of neural stem cell-based therapeutics for the treatment of disorders of the central nervous system (CNS) like ischemic paraplegia, traumatic spinal cord injury and amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, for which no effective treatments exist. In trials conducted at the University of San Diego, the Company's novel therapeutics demonstrated unprecedented levels of neuronal cell regeneration and integration in pre-clinical trials on rodent and mammal models with ischemic paraplegia. Several subjects experienced nearly complete functional recovery, dispelling the nearly common notion that damaged nerve cells cannot be regenerated and re-integrated into surrounding tissue.
Management expects to file the Company's first Investigational New Drug application (IND) requesting human clinical trials before the end of 2008, based on robust pre-clinical data. The event will mark a significant turning point for the Company, and could prove a interlude to a series of transformative events that will have a profound impact on the valuation of CUR shares.
CONTACT: Scott Butler, Director of Research and Managing Principal, Rock Creek Research Associates Tel: +1 503 690 7400 e-mail: scott@rcresearchonline.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
